L-Glutamine and Reduced Hospitalization

• A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.

  • 2018-07-19
  • RCT · n = 230
  • The New England journal of medicine 379(3)
  • • Yutaka Niihara
    • Scott T Miller
    • Julie Kanter
    • Sophie Lanzkron
    • Wally R Smith
    • Lewis L Hsu
    • Victor R Gordeuk
    • Kusum Viswanathan
    • Sharada Sarnaik
    • Ifeyinwa Osunkwo
    • Edouard Guillaume
    • Swayam Sadanandan
    • Lance Sieger
    • Joseph L Lasky
    • Eduard H Panosyan
    • Osbourne A Blake
    • Tamara N New
    • Rita Bellevue
    • Lan T Tran
    • Rafael L Razon
    • Charles W Stark
    • Lynne D Neumayr
    • Elliott P Vichinsky

  • PubMed: 30021096
  • DOI: 10.1056/nejmoa1715971

  2 Insights on

  • Reduced Hospitalization

  • High evidence
  • Large Human Trial
  • Highly Cited
  • Clinical

  Fewer hospitalizations occurred in the l-glutamine group than in the placebo group (P=0.005), with a median of 2.0 in the l-glutamine group and 3.0 in the placebo group.

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  0.3 g per kilogram of body weight per dose twice daily

• The GLOBE Trial: Efficacy and Safety of L-Glutamine Plus Hydroxyurea Versus Hydroxyurea Alone in Sickle Cell Anemia - A Double-Blind, Randomized Study

  • 2026-02-10
  • RCT · n = 53
  • Turkish journal of haematology : official journal of Turkish Society of Haematology 43(2)
  • • Nader Shakibazad
    • Moslem Momenzadeh
    • Batool Amiri
    • Marzieh Mahmoodi
    • Mani Ramzi

  • PubMed: 41664386
  • DOI: 10.4274/tjh.galenos.2026.09709

  5 Insights on

  • Reduced Hospitalization

  • High evidence
  • Clinical

  Hospitalizations declined by 40% (p=0.04)

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

  Dose

  not specified in abstract